Ocular Therapeutix, Inc. provided revenue guidance for the full year 2022. For the year, the company expected total net product revenue to be in the range of $55 million to $60 million, representing growth of between 26% to 38% over 2021. The growth is anticipated to be primarily driven by sales of DEXTENZA for the treatment of post-surgical inflammation and pain.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.75 USD | +14.09% |
|
+16.40% | +28.92% |
Jun. 14 | Sector Update: Health Care Stocks Decrease Late Afternoon | MT |
Jun. 14 | Ocular Therapeutix Shares Rise Following Clinical Development Progress Report | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.92% | 891M | |
+50.70% | 791B | |
+41.96% | 630B | |
-7.15% | 350B | |
+18.77% | 328B | |
+8.79% | 298B | |
+18.02% | 246B | |
+1.27% | 225B | |
+11.95% | 218B | |
+3.68% | 160B |
- Stock Market
- Equities
- OCUL Stock
- News Ocular Therapeutix, Inc.
- Ocular Therapeutix, Inc. Provides Revenue Guidance for the Full Year 2022